Looking at muscle selection and the dose of aboBoNT-A injections used for the treatment of pediatric upper limb spasticity

Study number: HED01251-11-11. Date of summary: June 2021
Study start date: April 2014. Study end date: December 2016

Please note that this summary only contains information from the full scientific article. For more information on this study, please visit: [www.ipsenmedicalinformation.com](http://www.ipsenmedicalinformation.com)

What was this study about?

This summary describes how doctors treated children with cerebral palsy (CP) for upper-limb spasticity with a medicine containing botulinum toxin, called aboBoNT-A, by injecting it into specific muscles in the children's elbows and wrists. Researchers wanted to better understand what dose of aboBoNT-A to use and which muscles they should inject when treating PUL spasticity.

What were the main conclusions of this study?

This study shows that while most children received injections of aboBoNT-A in the muscles of the elbows and wrists, doctors chose a wide variety of other muscles for injection to meet individual children's needs. In the Dysport in PUL spasticity study, researchers showed that injections of aboBoNT-A improved arm movement in children with CP.

Across all 4 treatment cycles, the most common upper-limb muscles chosen for injection to meet individual children's needs.

What was the purpose of this plain language summary?

The purpose of this plain language summary is to help you to understand the findings from recent research.

What did the researchers want to find out?

Researchers wanted to better understand what dose of aboBoNT-A to use and on which muscles they should inject when treating PUL spasticity.

What did the researchers find?

The results also suggest that aboBoNT-A may be effective at lower doses than those currently recommended in treatment guidelines.

Children aged 2–17 years old who had CP and PUL spasticity were included in this study. Overall, 210 children received aboBoNT-A injections.

The full title of this article is: Muscle selection and dosing in a phase 3, pivotal study of aboBoNT-A injection in upper-limb muscles in children with cerebral palsy.

We thank all of the patients who took part in this study. Without their support, advances in treatments for medical conditions would not be possible.

This study was sponsored by Ipsen.

Plain language services were funded by Ipsen.

Summary prepared by Jake Evans, PhD, at Envision Pharma Group.